Unimet Tablet 50/1000mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Union Pharma Co., Ltd.
MFDS item code 201506700 · Approved 2015.09.23
This product's status changed to Expired on 2025.09.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used together with sitagliptin and metformin to assist patients with type 2 diabetes in controlling their blood sugar levels. When taken along with lifestyle modifications such as diet control and exercise, it helps effectively manage blood sugar levels. This medication plays an important role in diabetes management by improving blood sugar control.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom this medicine must not be administered). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering medicines to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom this medicine must not be administered).
This medication consists of two ingredients, each used for diabetes treatment. The first ingredient is sitagliptin, and during treatment, serious allergic reactions may occur, requiring caution. Allergic reactions may include anaphylaxis, angioedema, severe skin reactions, etc. If these symptoms occur, discontinue the medication immediately and consult a physician. Additionally, sitagliptin can cause pancreatitis, a serious side effect involving inflammation of the pancreas; therefore, if abdominal pain, nausea, or vomiting occur during treatment, inform a physician immediately. The second ingredient, metformin, should not be administered to patients with impaired kidney function, dehydration, severe infections, or heart failure. This medication can accumulate in cases of reduced kidney function, leading to lactic acidosis, a rare but potentially fatal metabolic complication, so regular kidney function tests should be conducted during treatment. Metformin can also cause severe hypoglycemia; thus, caution should be exercised, particularly in cases of irregular meals, intense exercise, or concurrent use of other glucose-lowering medications. If hypoglycemic symptoms occur, take immediate action. Avoid alcohol consumption during treatment with this medication, and temporarily discontinue it before and after surgery. Additionally, this medication should not be used by women who are pregnant or breastfeeding. The safety and efficacy of this medication have not been established in children, and the elderly should use it cautiously due to a higher likelihood of impaired kidney function. During treatment, gastrointestinal disturbances, headaches, and infections may occur as side effects, and if severe joint pain, skin rash, or blisters develop, consult a physician immediately. This medication may interact with other drugs, so if you are taking other medications, be sure to inform your doctor or pharmacist. Regular blood tests and kidney function tests should be conducted to ensure safe use.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air ingress, ideally at room temperature between 1 to 30 degrees Celsius. This will help maintain the medication's effectiveness over time.
Dark red oval film-coated tablet
In-house packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Union Pharma Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.